New COPD inhaler shows promise in large trial
NCT ID NCT06643078
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 study tested a new inhaler called HL231 in 487 Chinese adults with moderate to very severe COPD. Participants used either HL231 or the active comparator Ultibro once daily for 52 weeks. The main goal was to see if HL231 improved lung function (FEV1) after 26 weeks compared to Ultibro. Secondary goals included reducing COPD flare-ups and tracking safety over the full year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HL231 (a combination of indacaterol and glycopyrronium) as an inhaled solution
What this could lead to
If successful, HL231 could offer a new once-daily inhaled treatment option for people with moderate to severe COPD, potentially improving lung function and reducing flare-ups.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The comparison is against an existing drug, so any advantage may be modest. Side effects and long-term safety are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China